Outbreak of ceftazidime-avibactam resistant Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae in a COVID-19 intensive care unit, Italy: urgent need for updated diagnostic protocols of surveillance cultures

J Hosp Infect. 2022 Apr:122:217-219. doi: 10.1016/j.jhin.2022.02.001. Epub 2022 Feb 6.
No abstract available

Publication types

  • Letter

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Azabicyclo Compounds
  • Bacterial Proteins
  • COVID-19*
  • Ceftazidime
  • Disease Outbreaks
  • Drug Combinations
  • Humans
  • Intensive Care Units
  • Klebsiella
  • Klebsiella Infections* / diagnosis
  • Klebsiella Infections* / drug therapy
  • Klebsiella Infections* / epidemiology
  • Klebsiella pneumoniae
  • Microbial Sensitivity Tests
  • beta-Lactamases

Substances

  • Anti-Bacterial Agents
  • Azabicyclo Compounds
  • Bacterial Proteins
  • Drug Combinations
  • avibactam, ceftazidime drug combination
  • Ceftazidime
  • beta-Lactamases
  • carbapenemase